908 Devices Inc. (MASS) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable...
Analysis Summary
908 Devices Inc. reported revenue of $56.2M in the most recent fiscal year, growing at a 5-year CAGR of 15.9%.
Trailing-twelve-month margins: gross margin 49.8%, operating margin -46.0%, net margin -56.7%.
At the current price of $9.92, MASS has negative trailing earnings (P/E not meaningful) and an ROE of -25.50%. Market capitalisation stands at $407M.
Balance sheet quality for MASS: current ratio of 4.2, net cash position of $96.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $9.92 |
| Market Cap | $407M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.80 |
| EV / EBITDA | -11.15 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -25.50% |
| Return on Invested Capital | -18.70% |
| Return on Assets | -17.46% |
| Gross Margin | 49.79% |
| Operating Margin | -46.01% |
| Net Margin | -56.68% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.67 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MASS | 908 Devices Inc. | $407M | 2.80 | -25.5% | |
| ALC | Alcon Inc. | $32.3B | 51.73 | 1.52 | 2.9% |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | 16.75 | 4.97 | 29.7% |
| 0A05.L | Medacta Group S.A. | $2.2B |
Price Performance
| 1 month | -1.59% |
| 3 months | +12.09% |
| Year-to-date | +88.95% |
| 1 year | +51.91% |
| 3 years | +62.09% |
| 5 years | -72.34% |
52-Week Range
| 52-week High | $11.25 |
| 52-week Low | $5.03 |
| Avg Volume (90d) | 350K |
Related companies: ACRS · CAPR · CERS · CVRX · NNOX · NPCE · QTRX
Explore sector: Healthcare · Medical - Specialties
More sections of MASS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks